Does pharmacogenetic testing optimize antidepressant effectiveness in major depressive disorder? Data from a double-blind randomized controlled trial in a real-world clinical setting

Abstract Background Major depressive disorder (MDD) exhibits significant heterogeneity in treatment responses, necessitating multiple pharmacological trials to achieve therapeutic success. Pharmacogenetic (PGx) testing has emerged as a promising tool to personalize antidepressant (AD) treatments, th...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Alessandra Minelli, Stefano Barlati, Stefano Bignotti, Valentina Menesello, Gabriele Nibbio, Giulia Perusi, Alessia Muscarella, Lisa Buson, Ughetta Bosco Umbertino, Paolo Martini, Rosana Carvalho Silva, Edoardo Spina, Giovanni Battista Tura, Antonio Vita, Massimo Gennarelli
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Cambridge University Press 2025-01-01
Saila:	European Psychiatry
Gaiak:	antidepressant treatment depression genetics pharmacogenetic testing randomized controlled trial
Sarrera elektronikoa:	https://www.cambridge.org/core/product/identifier/S0924933825101326/type/journal_article
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!